On March 1, 2024, Aptorum Group Ltd entered a Merger Agreement with YOOV Group Holding Ltd, where YOOV will become a wholly-owned subsidiary, and existing shareholders will hold approximately 90% and 10% of the combined company, respectively. Additionally, Aptorum will transfer its legacy business assets and liabilities to Aptorum Therapeutics Limited as part of the merger process.